Mostrando 3 resultados de: 3
Filtros aplicados
Publisher
European Journal of Clinical Pharmacology(1)
Journal of Psychopharmacology(1)
Therapeutic Drug Monitoring(1)
Área de conocimiento
Farmacología(2)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(3)
ODS 10: Reducción de las desigualdades(2)
ODS 9: Industria, innovación e infraestructura(2)
ODS 12: Producción y consumo responsables(1)
ODS 17: Alianzas para lograr los objetivos(1)
Origen
scopus(3)
Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes
ArticleAbstract: Sixteen hospitalized white European Spanish psychiatric patients treated with thioridazine alone werPalabras claves:CYP2D6, debrisoquine, Inhibition, ThioridazineAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P., Fernández-Salguero P.Fuentes:scopusQTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy
OtherAbstract:Palabras claves:debrisoquine, Haloperidol, QTcAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P.Fuentes:scopusQTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients
ArticleAbstract: Thioridazine cardiotoxicity has been associated with a prolonged heart-rate corrected QT (QTc) interPalabras claves:CYP2D6, debrisoquine, QTc lengthening, ThioridazineAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P.Fuentes:scopus